Natera (NASDAQ:NTRA)‘s stock had its “buy” rating reiterated by equities research analysts at Canaccord Genuity in a research report issued on Sunday, AnalystRatings.com reports. They currently have a $27.00 target price on the medical research company’s stock. Canaccord Genuity’s target price would suggest a potential upside of 48.92% from the stock’s current price.
Several other analysts have also weighed in on the company. Zacks Investment Research lowered Natera from a “hold” rating to a “sell” rating in a research note on Friday, March 8th. BidaskClub raised Natera from a “strong sell” rating to a “sell” rating in a research note on Wednesday, February 20th. Finally, ValuEngine raised Natera from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, January 15th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $28.00.
Shares of NASDAQ NTRA opened at $18.13 on Friday. The company has a current ratio of 2.11, a quick ratio of 1.99 and a debt-to-equity ratio of 2.28. Natera has a 52 week low of $10.77 and a 52 week high of $29.62. The firm has a market capitalization of $1.17 billion, a P/E ratio of -8.43 and a beta of 1.89.
In related news, insider Jonathan Sheena sold 190,286 shares of the firm’s stock in a transaction dated Friday, March 22nd. The stock was sold at an average price of $20.50, for a total value of $3,900,863.00. Following the sale, the insider now directly owns 355,621 shares of the company’s stock, valued at $7,290,230.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Michael Burkes Brophy sold 3,192 shares of the firm’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $16.00, for a total value of $51,072.00. Following the completion of the sale, the chief financial officer now directly owns 13,422 shares in the company, valued at $214,752. The disclosure for this sale can be found here. Insiders sold 351,313 shares of company stock worth $7,132,873 over the last ninety days. 13.18% of the stock is currently owned by insiders.
Several hedge funds have recently made changes to their positions in the company. Perkins Capital Management Inc. boosted its stake in shares of Natera by 121.3% during the first quarter. Perkins Capital Management Inc. now owns 129,900 shares of the medical research company’s stock valued at $2,679,000 after purchasing an additional 71,200 shares in the last quarter. First Manhattan Co. boosted its stake in shares of Natera by 98.8% during the first quarter. First Manhattan Co. now owns 1,027,242 shares of the medical research company’s stock valued at $21,181,000 after purchasing an additional 510,509 shares in the last quarter. Capital Impact Advisors LLC boosted its stake in shares of Natera by 25.5% during the fourth quarter. Capital Impact Advisors LLC now owns 102,617 shares of the medical research company’s stock valued at $1,338,000 after purchasing an additional 20,834 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Natera by 6.1% during the fourth quarter. Geode Capital Management LLC now owns 463,029 shares of the medical research company’s stock valued at $6,463,000 after purchasing an additional 26,771 shares in the last quarter. Finally, FMR LLC boosted its stake in shares of Natera by 57.0% during the fourth quarter. FMR LLC now owns 3,908,921 shares of the medical research company’s stock valued at $54,568,000 after purchasing an additional 1,419,390 shares in the last quarter. 87.76% of the stock is currently owned by hedge funds and other institutional investors.
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Featured Article: How Do You Calculate Return on Equity (ROE)?
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.